AA
CLVS

ALPS Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

ALPS Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-65,739
Closed -$3.47M – 979
2018
Q1 		$3.47M Buy
65,739
+11,425
+21% +$667K 0.03% 171
2017
Q4 		$3.69M Buy
+54,314
New +$3.8M 0.03% 153
2016
Q4 		– Sell
-49,083
Closed -$1.77M – 740
2016
Q3 		$1.77M Sell
49,083
-4,841
-9% -$104K 0.01% 191
2016
Q2 		$740K Buy
53,924
+10,828
+25% +$158K 0.01% 216
2016
Q1 		$827K Sell
43,096
-7,385
-15% -$156K 0.01% 196
2015
Q4 		$1.77M Sell
50,481
-8,354
-14% -$539K 0.02% 185
2015
Q3 		$5.41M Buy
58,835
+25,079
+74% +$2.17M 0.06% 108
2015
Q2 		$2.97M Buy
33,756
+16,810
+99% +$1.44M 0.03% 143
2015
Q1 		$1.26M Buy
+16,946
New +$1.2M 0.01% 174

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $7.71B AUM 4.02% 1-Year Est. Return

ALPS Advisors's CLVS Position: Q2 2018 in Review

ALPS Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q2 2018, closing a stake of 65,739 shares — an estimated $3.47M sold.

ALPS Advisors first reported a position in CLVS in Q1 2015 and held it in 9 quarters. The position peaked at $5.41M in Q3 2015. 210 funds tracked by Wall St. Rank hold CLVS as of Q2 2018.

  • ALPS Advisors reported no remaining Clovis Oncology, Inc. position as of Q2 2018 after selling out during the quarter.
  • ALPS Advisors sold 65,739 Clovis Oncology, Inc. shares in Q2 2018, an estimated $3.47M.
  • ALPS Advisors first reported a position in Clovis Oncology, Inc. in Q1 2015 and held it in 9 quarters.
  • ALPS Advisors's Clovis Oncology, Inc. position peaked at $5.41M in Q3 2015.
  • 210 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2018.

Based on ALPS Advisors's 13F filing for Q2 2018, filed 25 Jul 2018.